1. Pomerantz LLP investigates potential fraud claims against XOMA. 2. Rezolute, XOMA's partner, reported failed Phase 3 study results. 3. XOMA's stock fell 22.76% following the negative study results. 4. Investors may join a class-action lawsuit for alleged misconduct. 5. The failed study impacts future developments and investor confidence.
FAQ
Why Very Bearish?
XOMA's stock already dropped 22.76% due to poor clinical trial results. Historical cases show similar declines following failed studies, decreasing investor confidence.
How important is it?
The investigation and failed trial results are critical for XOMA's future. Investors are likely to be affected, making this information highly relevant.
Why Short Term?
Immediate investor reactions often follow bad news, suggesting ongoing volatility. Past trends indicate further declines until new positive data emerges.
Investor Alert: Investigation into XOMA Royalty Corporation by Pomerantz Law Firm
Pomerantz LLP has announced an ongoing investigation regarding potential claims on behalf of investors of XOMA Royalty Corporation (NASDAQ: XOMA). This inquiry seeks to determine if XOMA, along with certain officers and directors, has engaged in securities fraud or other unlawful business practices.
Details of the Investigation
Investors are urged to contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980 for more information. The primary focus of this investigation will assess the integrity of the company’s operations and financial disclosures, particularly in light of recent developments impacting XOMA's stock performance.
Impact of Recent Study Results
On December 11, 2025, Rezolute, Inc., XOMA's development partner, publicly shared results from its Phase 3 sunRIZE study regarding the drug ersodetug. The findings indicated that the study failed to meet its primary endpoint, which was to evaluate the change in average weekly hypoglycemia events in patients with congenital hyperinsulinism.
- The study reported an approximate 45% reduction in hypoglycemia events at the highest dose of ersodetug (10 mg/kg).
- This reduction was not statistically significant when compared to a placebo group, which experienced a 40% improvement.
- Furthermore, a key secondary endpoint revealed only a 25% reduction in average daily hypoglycemia time, again not statistically significant in comparison to the placebo.
Stock Performance Following Study Announcement
Following the announcement of these mixed results, XOMA's stock experienced a notable decline, falling by $7.82 per share, which equates to a drop of 22.76%, closing at $25.39 per share on December 19, 2025. This significant stock movement raises questions surrounding investor confidence and the company's future prospects.
Pomerantz Law Firm: A Leader in Securities Class Actions
Pomerantz LLP, a firm with a significant presence in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is considered a leader in corporate, securities, and antitrust class litigation. Founded by celebrated attorney Abraham L. Pomerantz, known as the “dean of the class action bar,” the firm has fought ceaselessly for the rights of those affected by securities fraud and corporate misconduct for over 85 years.
The firm has successfully recovered multimillion-dollar damages for class members, underscoring its commitment to achieving justice for investors. For further details on the ongoing investigation concerning XOMA, investors may visit www.pomlaw.com.
Contact Information
For inquiries regarding the investigation into XOMA Royalty Corporation, interested parties are encouraged to reach out to:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
Note: This announcement serves as attorney advertising. Prior results do not guarantee similar outcomes.